Abstract CT004: KEYLYNK-007: Tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency- positive advanced cancers

Abstract Background: Early data suggest poly (ADP-ribose) polymerase inhibitor (PARPi)/anti-PD-[L]1 synergy in homologous recombination repair-mutated (HRRm) or homologous recombination deficient (HRD) cancers. KEYLYNK-007 (NCT04123366) is a tumor-agnostic trial that evaluated the PARPi olaparib plus pembrolizumab in HRRm/HRD advanced tumors. Methods: This phase 2 trial enrolled participants (pts) with HRRm or HRD+ advanced solid tumors to 3 cohorts: BRCAm (except breast and ovarian), non-BRCA HRRm, and non-HRRm HRD. HRRm/HRD was centrally confirmed using the Lynparza HRR-HRD Assay before treatment with 300 mg olaparib BID + 200 mg pembrolizumab Q3W (≤35 cycles). Primary endpoint was ORR per RECIST 1.1 by central review. Secondary endpoints were duration of response and PFS per RECIST 1.1 by central review, OS, and safety. Results: At data cutoff (May 16, 2024), 332 pts were enrolled (n = 132 [BRCAm], n = 104 [non-BRCA HRRm], n = 96 [non-HRRm HRD]) (Table). Median follow-up was 13.4 (BRCAm), 10.4 (non-BRCA HRRm), and 10.8 months (non-HRRm HRD). ORR was 27% (BRCAm), 12% (non-BRCA HRRm), and 12% (non-HRRm HRD). Confirmed RECIST 1.1 responders beyond PARPi-approved indications included pts with advanced breast, ovarian, pancreatic, urothelial, renal, biliary, cervical, esophageal SCC, CRC, gastroesophageal adenocarcinoma, duodenal, small intestine, thyroid, salivary gland, HNSCC, NSCLC, SCLC, leiomyosarcoma, and other sarcomas. There were also multiple responses in HRRm prostate cancer. Grade ≥3 drug-related adverse events occurred in 30% pts; 1/332 (0.3%) pt died from septic shock. Conclusions: In this tumor-agnostic trial, olaparib plus pembrolizumab showed promising durable antitumor activity and manageable safety in HRRm and HRD+ (particularly BRCAm) advanced cancers beyond currently approved indications. Biomarker analysis is ongoing for other predictive biomarkers of response. Citation Format: Timothy A. Yap, Ronnie Shapira-Frommer, Iwona Lugowska, Tudor Ciuleanu, Miguel Quintela-Fandino, Özgür Özyılkan, Serhii Lysenko, Akira Hirasawa, Simcha Pollack, Rachel Salisbury, Alexander Gozman, Michele Maio. KEYLYNK-007: Tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency- positive advanced cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT004.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2025-04-25
DOI
https://doi.org/10.1158/1538-7445.am2025-ct004
Citations
7
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
7.32
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract CT004: KEYLYNK-007: Tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency- positive advanced cancers

Tudor–Eliade Ciuleanu, Miguel Quintela-Fandiño, Michele Maio, Alexander Gozman et al.
7 citations
Cancer Research
PARP inhibition in cancer therapy
7.32
article

Abstract CT004: KEYLYNK-007: Tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency- positive advanced cancers

Tudor–Eliade Ciuleanu, Miguel Quintela-Fandiño, Michele Maio, Alexander Gozman, Akira Hirasawa, Özgür Özyılkan, Iwona Ługowska, Ronnie Shapira‐Frommer, S. A. Lysenko, Simcha Pollack, Timothy Anthony Yap, R.E. Salisbury
article en
7 citations

Abstract

Abstract Background: Early data suggest poly (ADP-ribose) polymerase inhibitor (PARPi)/anti-PD-[L]1 synergy in homologous recombination repair-mutated (HRRm) or homologous recombination deficient (HRD) cancers. KEYLYNK-007 (NCT04123366) is a tumor-agnostic trial that evaluated the PARPi olaparib plus pembrolizumab in HRRm/HRD advanced tumors. Methods: This phase 2 trial enrolled participants (pts) with HRRm or HRD+ advanced solid tumors to 3 cohorts: BRCAm (except breast and ovarian), non-BRCA HRRm, and non-HRRm HRD. HRRm/HRD was centrally confirmed using the Lynparza HRR-HRD Assay before treatment with 300 mg olaparib BID + 200 mg pembrolizumab Q3W (≤35 cycles). Primary endpoint was ORR per RECIST 1.1 by central review. Secondary endpoints were duration of response and PFS per RECIST 1.1 by central review, OS, and safety. Results: At data cutoff (May 16, 2024), 332 pts were enrolled (n = 132 [BRCAm], n = 104 [non-BRCA HRRm], n = 96 [non-HRRm HRD]) (Table). Median follow-up was 13.4 (BRCAm), 10.4 (non-BRCA HRRm), and 10.8 months (non-HRRm HRD). ORR was 27% (BRCAm), 12% (non-BRCA HRRm), and 12% (non-HRRm HRD). Confirmed RECIST 1.1 responders beyond PARPi-approved indications included pts with advanced breast, ovarian, pancreatic, urothelial, renal, biliary, cervical, esophageal SCC, CRC, gastroesophageal adenocarcinoma, duodenal, small intestine, thyroid, salivary gland, HNSCC, NSCLC, SCLC, leiomyosarcoma, and other sarcomas. There were also multiple responses in HRRm prostate cancer. Grade ≥3 drug-related adverse events occurred in 30% pts; 1/332 (0.3%) pt died from septic shock. Conclusions: In this tumor-agnostic trial, olaparib plus pembrolizumab showed promising durable antitumor activity and manageable safety in HRRm and HRD+ (particularly BRCAm) advanced cancers beyond currently approved indications. Biomarker analysis is ongoing for other predictive biomarkers of response. Citation Format: Timothy A. Yap, Ronnie Shapira-Frommer, Iwona Lugowska, Tudor Ciuleanu, Miguel Quintela-Fandino, Özgür Özyılkan, Serhii Lysenko, Akira Hirasawa, Simcha Pollack, Rachel Salisbury, Alexander Gozman, Michele Maio. KEYLYNK-007: Tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency- positive advanced cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT004.

Cancer ResearchVol. 85(8_Supplement_2)
Okayama Shoka University (JP), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), The University of Texas MD Anderson Cancer Center (US), St. John's University (US), Okayama University (JP), Başkent University (TR), Sheba Medical Center (IL), Spanish National Cancer Research Centre (ES), Institute of Oncology Prof. Dr. Ion Chiricuta (RO), National Pirogov Memorial Medical University, Vinnytsya (UA), The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Openalex Percentile: Top 3%
PARP inhibition in cancer therapy
7.32
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.